Meeting
2015 ASCO Annual Meeting
A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer.
Authors
Kathleen N. Moore
University of Oklahoma Health Sciences Center, Oklahoma City, OK
Kathleen N. Moore , Anna M. Varghese , David Michael Hyman , Sophie Callies , Ji Lin , Volker Wacheck , Shubham Pant , Todd Michael Bauer , Johanna C. Bendell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
New Targets and New Technologies
Clinical Trial Registration Number
NCT01655225
Citation
J Clin Oncol 33, 2015 (suppl; abstr 11075)
DOI
10.1200/jco.2015.33.15_suppl.11075
Abstract #
11075
Poster Bd #
289
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).
First Author: Philippe L. Bedard
Poster
2017 ASCO Annual Meeting
Safety and tolerability of the dual PI3K/mTOR inhibitor LY3023414 in combination with fulvestrant in treatment refractory advanced breast cancer patients.
First Author: Anna M. Varghese
Poster
2023 ASCO Annual Meeting
A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Susanna Varkey Ulahannan
Poster
2021 ASCO Annual Meeting
Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.
First Author: Ecaterina Elena Dumbrava